MGRM | Monogram Orthopaedics, Inc.

Index- P/E- EPS (ttm)-0.49 Insider Own- Shs Outstand30.92M Perf Week2.81%
Market Cap135.73M Forward P/E- EPS next Y- Insider Trans- Shs Float2.20M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float / Ratio- / - Perf Quarter-
Sales0.00M P/S- EPS this Y- Inst Trans- Short Interest- Perf Half Y-
Book/sh0.72 P/B6.06 EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.02 - 48.99 Perf YTD-62.64%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-91.04% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low9.20% ATR4.03
Employees23 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility10.68% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.22 Prev Close4.80
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume924.82K Price4.39
Recom- SMA20-35.03% SMA50-35.03% SMA200-35.03% Volume207,823 Change-8.54%
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic and cadaveric bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.